论文部分内容阅读
替卡格雷是首个环戊基三唑嘧啶类药物,为可逆性的口服P2Y12受体拮抗药,阻断二磷酸腺苷(ADP)引导的血小板聚集。噻吩并吡啶类药物在血小板的生命周期中与P2Y12的结合不可逆,而替卡格雷与受体结合是可逆的,这种可逆性表现为起效的迅速性和抗血小板聚集作用消失的迅速性。动物实验显示其抗血栓形成的作用与引发出血的作用分离。不像噻吩并吡啶类药物,替卡格雷无需代谢活化,吸收迅速,迅速显示抗血小板作用,抗血小板
Ticagrelor is the first cyclopentyltriazolium drug, a reversible oral P2Y12 receptor antagonist, to block ADP-induced platelet aggregation. The thienopyridine drug is irreversibly bound to P2Y12 during the platelet life cycle, whereas the binding of ticagrelor to the receptor is reversible. This reversibility is characterized by rapid onset of action and rapid disappearance of anti-platelet aggregation. Animal experiments show that its anti-thrombotic effect and the role of bleeding induced separation. Unlike thienopyridines, ticagrelor does not require metabolic activation, rapidly absorbs rapidly and shows anti-platelet action, anti-platelet